Overview
Rybrevant is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer. It is specifically indicated for adults with locally advanced or metastatic non-small cell lung cancer…
Overview
Rybrevant Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that has specific…